VANCOUVER, Jan. 18 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX) today
announced interim results from its ongoing Phase I clinical trial evaluating
PRX302 in patients with localized, recurrent prostate cancer. The findings to
date indicate that PRX302 is well tolerated and shows encouraging signs of
therapeutic activity following a single intra-prostatic injection.
